The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Geisinger Health System sets higher accrual goals for DNA sequencing study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

GEISINGER HEALTH SYSTEM announced that 100,000 recruits have signed up for the health system’s major biobank and DNA sequencing study known as the MyCode Community Health Initiative.

Launched in January 2014 in collaboration with the Regeneron Genetics Center, the MyCode Community Health Initiative originally set out to recruit 100,000 study participants. That target, however, was reached in only two years. Geisinger researchers have set a new goal of at least 250,000 participants.

Geisinger’s study is also the largest in the United States that combines electronic health records linked to large-scale DNA sequencing data, according to the company.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalRegulatory NewsTrials & Tribulations

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
By Edison T. Liu
Sponsored

Why both somatic and germline genomic profiling are essential for precision oncology

Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 
By Heather Hampel and David W. Craig
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account